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INTRODUCTION
The world’s response to HIV/AIDS has generated tangible benefits, including the first-ever
widespread introduction of chronic care in resource-limited settings and an unprecedented
scaling up of medical services. The AIDS epidemic has brought renewed attention to
global health inequities, resulted in the establishment of innovative financing mechanisms
for health programs and prompted new resolve to strengthen fragile health systems in
developing countries.
Yet the HIV/AIDS epidemic continues to expand
because not enough progress has been made to slow
the rate of new HIV infections. Since the epidemic
first appeared 28 years ago, more than 60 million
people have become infected with HIV and more than
25 million have died.
In 2008 alone, 2.7 million people worldwide became
newly infected with HIV.1 The rate of the epidemic’s
expansion continues to outpace the response. For
every individual placed on antiretroviral therapy
in 2007, more than two individuals became newly
infected with the virus.2 In sub-Saharan Africa —
home to two out of three new HIV infections in 2008 —
HIV/AIDS has become endemic at extraordinarily high
levels.1 AIDS is now the number one killer of women
globally 15 to 44 years of age.3 In addition, survey data
from Swaziland, released in 2009, indicate that HIV
prevalence among pregnant women has increased
since 2006, reaching a concerning 42 percent.4
Studies have validated an array of effective HIV
prevention strategies — including behavioural
interventions, male and female condoms, voluntary HIV
testing and counselling services to prevent mother-tochild transmission, access to sterile injecting materials
and adult male circumcision. To date, however, these
strategies have not succeeded in lowering new
infections to a manageable rate.

Current HIV prevention options — especially for women
— are limited, and new self-initiated prevention options
are urgently needed. Vaginal microbicides, biomedical
products in the form of gels, rings, films and tablets,
are under development to reduce the transmission of
HIV to women during sex with an HIV-infected male
partner. These products would give women a new way to
protect themselves from HIV/AIDS, empowering them to
safeguard their health.
The International Partnership for Microbicides (IPM)
focuses on developing safe and effective microbicides
based on the same types of antiretroviral (ARV) drugs
already being used successfully to treat HIV/AIDS and to
prevent mother-to-child transmission of HIV. Microbicide
development is a long and complex process involving
many steps to test and introduce a new product. Years of
sustained involvement by a large number of researchers,
community health workers and clinical trial volunteers
are required to turn the hope of this medical research into
a reality.
Benefits from microbicide development are already
being reaped today, as the research required to develop
microbicides generates important immediate and
long-term gains. Research efforts both strengthen
clinical research capacity in the areas hardest hit by
the HIV epidemic and directly benefit the people and
communities that host clinical trials.
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Reducing women’s Risk of HIV/AIDS
Microbicide research strengthens medical research
capacity by:
ff building capabilities in geographical areas of need.
ff addressing the “10/90” research gap.
ff increasing and developing physical infrastructure and

human resources at research centres.
ff enhancing the understanding of epidemic trends

through HIV incidence studies.
ff developing the capability to conduct ethical,

high-quality clinical trials.
ff building the foundation to get new medical products

approved for use.

In addition, microbicide research can significantly
benefit the people, communities and countries that
host clinical trials by:

A Key Global Development Objective
The effect of HIV/AIDS on social and economic development
can be seen clearly in regions of high prevalence, such as
sub-Saharan Africa, where the epidemic is decreasing life
expectancy and reducing the number of individuals who
participate in various sectors of the economy.
At the end of 2008, more than 14 million children in Africa had
lost one or both parents to AIDS. Women and girls continue
to experience a heavy burden from HIV, accounting for
60 percent of all people living with HIV in sub-Saharan Africa.
In some countries, young women between 15 and 19 years
of age are three times more likely to be infected than their
male counterparts. In addition, women ages 20 to 24 are more
than five times more likely to be living with HIV than men of
the same age group. 1

Sub-Saharan Africa: Addressing the Greatest Need

ff promoting health and HIV awareness.
ff empowering women through education and

counselling.
ff involving men in HIV prevention.
ff encouraging HIV testing.
ff strengthening the access to health services.
ff engaging communities and building community

advisory platforms.
ff providing employment and professional development

Worldwide HIV Prevalence, 2008
Sub-Saharan Africa (67%)
East, South & South-East Asia (14%)
Caribbean & Latin America (6%)
Eastern Europe & Central Asia (4.5%)
North America (4%)
Western & Central Europe (2.5%)
Middle East & North Africa (1%)
Oceania (<1%)
Source: AIDS Epidemic Update: November
2009, p12. United Nations Programme on
HIV/AIDS (UNAIDS) and World Health
Organization (WHO) joint publication.

opportunities.
The promise of microbicides to prevent HIV infection
continues to provide hope for the future. As microbicide
research moves us closer to this goal, it directly advances
the global health agenda, including the United Nation’s
Millennium Development Goals (MDGs), and delivers
important benefits to the people, communities and
countries of today.
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Women are biologically more susceptible to HIV transmission
than men during heterosexual intercourse. In addition,
women experience persistent social, legal and economic
disadvantages that increase their vulnerability to HIV.
Women and girls frequently lack the means to persuade their
male partners to use condoms or remain faithful.
The health and well-being of the world’s women and
girls — IPM’s primary concern — is at the heart of the global
development agenda. In addition to calling on the world
to halt and, ultimately, to reverse the global HIV epidemic
by 2015, the MDGs envision concrete progress towards
gender equality and improved maternal health, as well as a
reduction in other global health and economic inequities.
While working to develop new medical technologies that
will reduce women’s risk for HIV infection, IPM and its
partners also actively focus resources to improve health and
build capacity.

The Role of Microbicides in Advancing the UN Millennium Development Goals
In 2000, global leaders gathered at the United Nations
to chart an ambitious development agenda for the
new century, agreeing on eight overarching goals to
be achieved by 2015. The microbicide field is working
to accelerate progress toward these aims. Microbicides
would directly contribute to progress on six of the MDGs
and yield considerable indirect benefits toward other
development goals, including:

Goal 3: Promote gender equality and empower
women — Access to microbicides would empower
women to protect their own health. As the UN Millennium
Task Force found, “A large body of evidence shows that
sexual and reproductive health and rights are central
to women’s ability to build upon their capabilities, take
advantage of economic and political opportunities and
control their destinies.”

Goal 1: Eradicate extreme poverty and hunger —
HIV/AIDS deepens poverty and exacerbates income
inequities. By helping to lower HIV incidence, microbicides
would contribute toward the global goal of cutting the
poverty rate in half.

Goal 4: Reduce child mortality — By reducing HIV
incidence among women, microbicides would play a key
role in lowering the number of babies born annually with
HIV, thereby reducing childhood illness and death.

Goal 2: Achieve universal primary education —
By reducing the number of new HIV infections,
microbicides would help reduce the number of teachers
lost to AIDS and prevent households from withdrawing
children from school to cope with HIV-related illnesses in
the family.

Goal 5: Improve maternal health — By helping women of
reproductive age to remain healthy, microbicides would
increase women’s productivity and reduce the number of
children being orphaned.
Goal 6: Combat HIV/AIDS, malaria and other diseases —
Women represent one out of two people living with HIV
globally, so microbicides could play a key role in reversing
the global epidemic.
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Developing Microbicides to Save Lives
IPM Microbicide
Development
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IPM is a nonprofit product development partnership
(PDP) established in 2002 to prevent HIV transmission
by accelerating the development and availability of
microbicides for use by women in developing countries. It
coordinates, contributes funding to and directly conducts
the different phases of work needed to bring microbicides
from initial laboratory testing and subsequent clinical
development to final regulatory approval and product
distribution.
Microbicide products are being developed based on the
same types of ARVs that are being used to treat HIV/AIDS
and prevent mother-to-child transmission of HIV. Work is
underway to identify the most promising ARV drugs or
combinations of drugs that would be suitable for use as
microbicides. ARV-based microbicides would work in a
variety of ways by either preventing HIV from attaching to
or entering a healthy human cell, or by preventing the virus
from making copies of itself once it is inside a cell.
Microbicides can be provided in a variety of product
formulations, with the goal of giving women greater
choice and convenience. Microbicide gels were the most
common formulation tested in early generation trials,
but those products needed to be applied shortly before
sexual intercourse. Newer formulations currently under
development include once-daily vaginal gels, films and
tablets, as well as vaginal rings that would provide up to
one month’s protection from HIV. All of these formulations
could potentially be used independently of sexual activity,
offering more convenience and providing protection during
anticipated or unanticipated sex. Over time, microbicide
products could be formulated to offer contraception in
addition to HIV protection.
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A rigorous, step-wise approach is taken to developing new
microbicide products by:
ff supporting preclinical research needed to prepare

products for clinical trials.
ff developing new formulations or drug delivery

approaches.
ff partnering with clinical research centres in both

developing and developed countries to conduct the
clinical trials needed to evaluate the safety, efficacy and
acceptability of candidate microbicides.
From its inception in 2002 through 2009, IPM completed
eight clinical trials studying the safety and pharmacokinetics
(PK) of microbicide gels and rings. Six additional safety
and/or PK trials in Africa, Europe and the United States are
ongoing. Eleven epidemiological studies of HIV incidence
were completed in Africa, with two more under way.
Additionally, two market research studies assessing the
acceptability of placebo vaginal gels, films, tablets and soft
gel capsules were conducted in five countries in Africa.
In total, as of May 2010, IPM had completed or initiated
29 studies. At least five more clinical trials are planned at
various locations. A Phase III programme testing the safety
and efficacy of dapivirine, IPM’s most advanced microbicide
candidate, is scheduled to begin in 2011.

Partnering to Accelerate Microbicide Development
Product development partnerships (PDPs) such as
IPM are nonprofit organisations created to accelerate
the development of new tools to fight disease in
resource-limited settings. PDPs manage resources
and partnerships from across public, private and
philanthropic sectors to develop new products that
advance global development goals and could potentially
save millions of lives.
Since 2004, IPM has obtained several non-exclusive,
royalty-free licenses from pharmaceutical companies to
develop, manufacture and distribute ARV compounds as
microbicides in developing countries.

IPM does not and will not profit from its work to develop
microbicides. Pharmaceutical companies have given IPM
the right to develop compounds as vaginal microbicides
for HIV prevention and to distribute them to women in
developing countries at low or no cost.
Such agreements serve as a model of public-private
partnership in fostering global health solutions. Sample
contract structure and consultations are available to
other product developers seeking to negotiate similar
agreements with the private sector, on behalf of greater
public health goals.

Compound

License

Mechanism*

Dapivirine

Tibotec/Johnson & Johnson

Reverse transcription — Stops virus from copying its genetic material
inside human cells

L167, L872, L882

Merck

Cell attachment — Prevents virus from attaching to human cells

BMS793

BMS

Cell attachment — Prevents virus from attaching to human cells

Tenofovir
(IPM & CONRAD)

Gilead

Reverse transcription — Stops virus from copying its genetic
material inside human cells

Maraviroc

Pfizer

Cell attachment — Prevents virus from attaching to human cells

L’644 peptide

Merck

Cell Fusion — Prevents virus from entering human cells

* Step blocked in the HIV life cycle

Ensuring Access
Once developed, microbicides must be made widely
available and affordable. Historically, it can take decades
for the benefits of scientific innovation to reach emerging
or developing countries. IPM and the broader microbicide
field are committed to expediting widespread availability
and access of all effective products, reaching those most in
need first.
Microbicide developers are fundamentally committed
to the principle that all participants in microbicide trials
should have access to the product studied once it has
proven to be safe and effective, and has been approved
for use in the country. Ensuring access to microbicides
is a responsibility that must be shared by trial sponsors,
research teams, donors, multilateral and bilateral agencies,
and national governments.
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Building CLINICAL Research Capacity

• Infrastructure & equipment
• Communications & Financial
training

• Employment opportunities
• Staﬀ training & development

Capacity Building at
Research Centres

“We have staff that came to us with no research skills, and they have been trained by IPM.
In terms of career development, they are able to go further with their education through the
experience they’ve gained.”
— Site Manager, Reproductive Health and HIV Research Unit, South Africa

Addressing the “10/90” Research Gap
The communities in Africa where IPM is conducting
microbicide research are among those most heavily affected
by HIV/AIDS. Continued research holds the promise to help
these and other regions combat their national epidemics.
Along with this hope, research efforts also generate
immediate and long-term benefits by building clinical
research capacity in sub-Saharan Africa. Microbicide research
builds additional infrastructure and helps job creation in
those regions where research is conducted.
In recent years, growing concern has focused on what has
come to be called the “10/90” research gap — a short-hand
reference to the fact that only about 10 percent of global
medical research spending is focused on the health problems
in developing countries that carry about 90 percent of the
world’s health burden. To help eliminate the “10/90” research
gap, it is essential to increase research capacity in countries
where these products are most urgently needed. IPM’s core
mission to develop microbicides directly addresses this gap.
Clinical trials designed to evaluate potential new health
products, such as microbicides, must be conducted in the
populations where such products would be used.

Investments have already expanded research capacity and
understanding of HIV/AIDS in the communities that host
clinical trials. IPM is collaborating with more than 15 local
research centres in seven countries in Africa (Kenya, Malawi,
Rwanda, South Africa, Tanzania, Zambia and Zimbabwe).
About half of the research centre partners were newly
established with IPM’s support. The remainder were preexisting clinical research institutions whose infrastructure,
equipment and staff training have been enhanced.
For example, a new research centre established through
IPM funding in the KwaZulu-Natal province of South Africa
is located in a community where more than 40 percent of
women between 18 and 35 years are HIV-infected. This new
centre is now conducting IPM microbicide clinical trials and
collaborating with a local organisation that provides ARV
treatment, home-based care, and support for orphans and
vulnerable children in the community.
“We had rented the upper story of an NGO building for the new research
centre. We ripped it apart and started from scratch with IPM support all
the way through, including infrastructure, all the equipment and the
appointment of staff. We’ve recently modified the accommodation to
handle colposcopy needs and additional lab needs.”
– Principal Investigator, Prevention of HIV/AIDS Project (PHIVA), South Africa
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IPM-sponsored research and activities in Africa

BURKINA
FASO

KENYA
RWANDA
TANZANIA

ZAMBIA

MALAWI

ZIMBABWE

Ongoing studies or activities

SOUTH AFRICA

A Three-Part Process is Used to Build Research Capabilities
Building Research Centre Infrastructure: An important
first step is to conduct a comprehensive assessment of each
research centre’s readiness and to evaluate the quality and
accessibility of primary health and social support services
in the local area. Funding and support is then provided
for building or expanding the research centre’s physical
infrastructure as well as its human resource capacity. IPM
also offers guidance on developing standard operating
procedures (SOPs) at the centre, provides training and
equipment needed to ensure that trial-related procedures
and laboratory tests are performed in accordance with
international and national Good Clinical Practice (GCP)
standards, and advises on community outreach and
education activities.
Understanding HIV Incidence: Epidemiological studies
of HIV incidence are designed to assess, through regular
HIV testing and counselling, the rate of new infections in
a community. These studies help identify settings that are
suitable for microbicide efficacy trials, but they also help
build the case for the pressing need to fight HIV/AIDS among
women. By early 2010, IPM had sponsored HIV incidence
studies in 10 communities across Africa and had begun
planning for similar studies in additional communities. Studies

that detail HIV prevalence and incidence rates among women
of reproductive age can aid national and local authorities
in devising strategies to address the needs of women who
continue to be at extremely high risk of HIV infection.
Conducting Clinical Trials: Training and capacity building
are continued at research centres to support the staff in
conducting high-quality clinical trials in accordance with
international and national GCP standards.

Partnering With Other PDPs Further Increases Capacity
Partnerships have been created with other PDPs working
on new HIV prevention technologies to increase the
capacities of all involved. For example, collaboration with the
International AIDS Vaccine Initiative (IAVI) to use its safety
laboratory in Kigali, Rwanda, for analysing samples from
IPM trials eliminated the need to build a new laboratory for
this purpose. IPM also partners with research centres that
were previously involved with HIV vaccine trials, such as
the Desmond Tutu HIV Foundation centre in Nyanga, South
Africa, the Africa University centre in Mutare, Zimbabwe,
the Zambia-Emory HIV Research Project centres (supported
by IAVI) in Lusaka and Ndola, Zambia, and the University of
North Carolina Project in Lilongwe, Malawi.
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“I had never participated in research, so I learned the science and then became the
coordinator of the HIV cohort study. Later I coordinated a vaginal ring study. When I
look at where I came from, it’s amazing how much I’m able to do now.”
— Project Officer, International Centre for Reproductive Health, Kenya

Employment and Professional Development
Microbicide research augments the number of professional
opportunities available to clinical researchers in Africa.
Microbicide studies provide professional opportunities for
both well-established experts and newly qualified scientists
to advance their scientific careers in their home countries.

Professional Development Training for Research
Centre Staff
140
Trainings:

120

GCP, GPP, QA/QC
Lab tests, GCLP
90
Community
engagement
Study-specific
training

60

Clinical safety
Socialbehavioural

30

Finance/Budgeting
Communications

0
2007

2008

2009

GCP = Good clinical practice
GCLP = Good clinical laboratory practice

GPP = Good pharmacy practice
QA/QC = Quality assurance/Quality control

“This is also a way for us, the more mid-level researchers, to pass on our
knowledge to the next generation. And we’re hoping that some of these
students that we’re currently training will go on to become investigators,
so that all of these research projects become sustainable.”
– Study Investigator, Projet Ubuzima, Rwanda

Research centres employ a wide range of staff, including
key technical staff, namely physicians, nurses, counsellors,
pharmacists and lab technicians as well as other professionals
such as community liaison staff, management, finance and
administrative staff.
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In addition to obtaining experience in conducting complex
clinical trials, local researchers benefit from ongoing
professional development activities. IPM conducted more
than 200 training events for research centre staff in Africa
between 2007 and 2009. Additional training was conducted
in Europe and the United States. Representatives from centres
in Africa at which IPM conducts studies also come together
for annual clinical affairs meetings, where new developments
are discussed, and challenges and successes are shared. In
2009, 77 research centre staff attended the five-day meeting in
Nairobi, Kenya.
Non-technical research centre staff also gain experience
that supports their professional development. For example,
training is provided for financial management, community
education and engagement, counselling, social-behavioural
science and communications.

Ethical Conduct of Clinical Trials
IPM is committed to sponsoring clinical trials that meet
international and local standards, and receive approval from
national regulatory agencies and local ethics committees.
Conduct of clinical trials with rigorous standards not only
protects the health and rights of clinical trial volunteers, but
also helps research centre staff learn how best to conduct
high-quality clinical research. As part of the ethical conduct
of trials, research centres ensure that each woman who
volunteers for a microbicide clinical trial gives her consent
freely, based on a clear understanding of the trial, including
the potential risks and benefits of trial participation.
Informed consent is an ongoing process that requires
periodic discussions with participants.

Getting Approvals for Clinical Trials and New Products
The European Commission, with IPM’s facilitation, sponsors
annual consultations of representatives from regulatory
agencies and ethics committees across Africa. These sessions
help build a common understanding of key issues related to
microbicide and other HIV prevention research throughout
the African region. The meetings serve as a forum to share
best practices on standards of care, safety evaluation
and factors affecting product efficacy. They also address
approval processes for clinical trial protocols, community
outreach, and future access to products. Once the first safe
and effective microbicide is developed, IPM and its partners
will move rapidly to get the new product approved and
distributed first in Africa to meet the needs of women to
prevent HIV transmission.

Improving Lives and health
Benefiting Clinical Trial Participants
Many clinical trial participants live in settings where HIV
prevalence is high and where access to basic health services is
limited. Women who participate in clinical trials receive care or
referrals to medical services that help improve their health.
Participants of both clinical trials and epidemiology studies
receive regular HIV tests, risk reduction counselling, and free
access to condoms. Participants are also assessed for other
common sexually transmitted infections (STIs) and offered or
referred for treatment for curable STIs that are identified.
Participants obtain family planning services and receive
ongoing contraceptive counselling for the duration of the
trial. Participants who nevertheless become pregnant will
discontinue use of the investigational product and will be
referred to the appropriate clinic for further management of
the pregnancy while continuing to be monitored for safety
by research centre personnel.
Trial participants who, despite risk reduction counselling, may
still be unable to protect themselves and become HIV-positive
during the time period of the trial are referred for appropriate
HIV-related care and ARV treatment.
Testing volunteers for HIV regularly provides value since it
can alert women who otherwise may not have known of
their HIV status. Individuals who test positive for HIV during
pre-trial screening also receive referrals for support and care.
“I’m personally convinced that the voluntary counselling and testing, and
handing out condoms during a study do have an effect on HIV incidence. If
you do the counselling well, it’s definitely possible to lower the incidence.”
— Study Investigator, Projet Ubuzima, Rwanda

Empowering Women Through Education and Counselling
The regular health counselling received by trial participants
helps mainstream primary health care and health literacy.
According to a physician working at an IPM research centre in
Kenya, “Women are coming to the clinic and learning about
essential tests and services like Pap smears and complete
cervical check-ups. It has enhanced their health-seeking
behaviours.”

There is also evidence that women who participate in clinical
trials benefit from the regular HIV prevention counselling
they receive, including learning new skills to negotiate safer
sex and protect themselves from risky situations. “Women
who participated in one IPM study felt more confident
to negotiate safer sex because they had the information
and the tactics, and they knew they had a right to protect
themselves,” one research centre staff member said.
“Study participants really appreciated a full medical exam — that’s
something they never get anywhere else — including tests which can pick
up things… like a blood disorder. We’d then be able to refer her to the
local university hospital. We’re also picking up asymptomatic STI cases…
there are probably many of those cases out there that we don’t even know
about.”
— Principal Investigator, Madibeng Centre for Research, South Africa

Improving HIV Awareness
Through community education and recruitment efforts,
research centres raise awareness about the epidemic and
its risks. As a principal investigator in South Africa observed,
“Our work is sort of opening up people’s minds, because
when we are recruiting or mobilizing or raising awareness,
we are talking about HIV/AIDS. We broadly open up
discussion about HIV in our communities.”
These efforts are producing tangible prevention benefits.
“Individuals who are reached by IPM research activities are
more aware of how to be healthy, and how they should behave
to reduce their risk of infection,” a study coordinator said.
IPM is helping reach girls and young women in Africa, as well
as their male partners and the communities in which they
live, with HIV education and awareness. In South Africa, for
example, research centre staff have built links with schools
giving them an opportunity to engage in dialogue with
young adults. Research centres host special community
events to raise awareness about the disproportionate risk of
infection in women and the ways in which men and women,
young and old, can protect themselves.

“The new doctor who is working with us has never had the opportunity to do microscopy
before. He is now thinking he should also do microscopy in his practice. Normally he would
send everything to the lab, but in his setting, laboratory tests are not affordable, so he’d be
able to pick up those things without needing to send them out.”
— Principal Investigator, Madibeng Centre for Research, South Africa
Microbicide Research: Hope for the Future, Benefits for Today 9

Encouraging HIV Testing and Helping to Reduce Stigma
Regular HIV testing for participants in HIV incidence studies
and microbicide clinical trials helps to encourage HIV testing
and promotes knowledge of HIV status. There are also
additional broader efforts under way to increase community
awareness about the benefits of HIV testing. This represents
a concrete contribution to the broader HIV response, as
inadequate testing rates continue to impede more effective
action on AIDS. In Kenya, for example, authorities estimate
that 84 percent of people living with HIV are unaware of
their status. As a Kenyan Project Officer reported, “People
in the community are more comfortable going for HIV
testing because it’s not the end of the road for them. I asked
a local religious leader, ‘What is the one thing that IPMsponsored studies have done for the women here?’ He said,
‘It demystified HIV testing. People used to be afraid to go for
HIV testing. Now that fear is not as much as it used to be.’”

Microbicide development efforts contribute to improving
the capacity within communities to deliver key health
care services that are related to the research being done.
IPM supports infrastructure improvements and additional
capacity needed by its sponsored research centres. Links
are also created or strengthened between research centres
and public health clinics and hospitals that can serve as
referral facilities.
A new IPM-funded research centre, Be Part Yoluntu Centre,
opened its doors in 2007 in Western Cape, South Africa. The
centre was established with IPM support and was able to
obtain additional financing that allowed it to initiate an afterhours voluntary counselling and HIV testing service for men.
The centre has completed one IPM HIV incidence study and
is currently conducting clinical trials examining the safety of
the vaginal microbicide, dapivirine.
An IPM-sponsored research centre near Durban, South
Africa, is working towards becoming a centre for delivering
family planning services to its community. The site was
offering family planning to microbicide trial participants
when local government officials recognised the value of the
services provided.
“We’re currently a family planning site, in a way. We submit statistics to
the municipal district office, and there is a partnership between us and
them. We’re getting a lot of requests from participants … they want to
come back and continue to get family planning even after the study ends.”
— Principal Investigator, Reproductive Health and HIV Research Unit,
South Africa

Engaging Communities and Expanding the Delivery
of Health Services
Research activities are undertaken in close partnership
with local communities. All IPM research centre partners
design and implement a community engagement program
to support partnerships between researchers and the
community. These efforts build community support for
participants and the research itself and foster strengthened
relationships with local authorities and other stakeholders.
Community outreach promotes regular contact with local
clinics, community leaders, traditional healers, teachers’
associations and public health officials.
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“I’ve seen many changes in the community where an IPM
study is going to take place,” reported a community liaison
officer at an IPM-sponsored research centre in Malawi. “With
the building in the area, community members see it as
‘someone’ coming in to do something in their community.
The clinic built for the IPM study has staff that build stronger
relationships with the government health workers. The IPM
community educator assists in HIV prevention talks at the
government clinics and in the larger community.”

“We have a community goal, and a very strong one. With the community engagement
unit through IPM, we have better structures. They have helped and built our capacity
as leaders, and we can now grow and make community engagement and community
— Project Officer, International Centre for Reproductive Health, Kenya
participation a more visible item.” 
Community Advisory Boards and Groups
Each IPM research centre partner is linked to a Community
Advisory Board or Group (CAB/CAG). These serve as
educational conduits between the research centre and the
community, help ensure support for the clinical trials as well
as voice suggestions or concerns from the community. They
also help increase the number of community members and
advocates who are knowledgeable about clinical research.
These bodies often include former clinical trial participants,
prominent community leaders, opinion leaders, religious
leaders and people living with HIV/AIDS.

Another benefit of research is the involvement of men
in HIV prevention efforts. Research centres serve as
a hub from which information about HIV/AIDS, HIV
prevention and HIV treatment can flow to community
members, both women and men.
According to the manager of a research centre in
South Africa, “There are general community members
— many men — who come to the site to get more
information about HIV issues. It really helps ordinary
members of the community with sexual behaviour.
There has definitely been a great change.”

Community Advisory Boards/Groups
250
228

2007
2009

200

145

150

Between 2007 and 2009, the number of CABs and CAB
members increased markedly. During this time, IPM also
sponsored more than 60 training events, meetings and
workshops, addressing such topics as product adherence,
counselling and outreach for community staff at research
centres.

100

50

8
0

CABs/CAGs meet on a regular basis and provide a liaison
between clinical research centres and the communities
where clinical trials take place. These groups provide input
on important subjects such as informed consent. In some
cases, IPM’s support and guidance enabled research centres
to assemble a CAB or CAG for the first time. IPM conducted
two regional workshops during 2009 — in Rwanda and
South Africa — for CAB/CAG members from communities
and countries in which IPM clinical trials are ongoing or
planned.
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CABs/CAGs

Members

“We have open days and women’s days. Once we had someone come
to talk about Pap smears and cancer, it was quite enlightening for the
community. And for women’s day, we had a lot of young people there. We
had a panel talking about violence against women, HIV/AIDS and ARVs,
etc. There is a lot of impact in the community from this study.”
— Principal Investigator, Reproductive Health and HIV Research Unit,
South Africa
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Conclusion
While working to advance its primary mission of developing
safe and effective microbicides for HIV prevention, IPM
is producing tangible benefits today for the people,
communities and countries that host its clinical trials and
epidemiological studies. These benefits directly advance
the UN Millennium Development Goals endorsed by the
international community and bring value to the very
communities where HIV/AIDS burden is the highest.

Communities also benefit from hosting clinical trials.
Enhancing existing facilities and creating new clinical
research centres provides employment and professional
development for people of many backgrounds. Clinical
trial participants receive medical screening, education and
counselling, leading to better HIV awareness. Outreach and
engagement programs based at the centres also enhance
health and HIV awareness among community members.

Microbicide development builds medical research capacity,
infrastructure and staff expertise. This capacity is being built
in the areas of greatest HIV/AIDS burden, thereby helping
to address the “10/90” research gap. Capacity building
encompasses both physical infrastructure and human
resources, helping to create research centres with the
equipment, facilities and staff needed to carry out effective
and ethical clinical trials. HIV epidemiological studies
promote a better understanding of HIV prevalence and
incidence rates in the studied areas.

Developing tools, such as microbicides, that empower
women to protect their health and save lives is of key
importance to stem the tide of HIV infection. IPM is
dedicated to turning this hope for the future into a reality,
and is committed to continuing to generate benefits for the
people, communities and countries of today.

“I have been working in Africa for 15 years in multiple countries, and the one big thing
that I see changing is that the mindset of people has become a bit more research oriented.
Now, people are finally equipped with the tools. It’s a different way of thinking if you do
research; it’s also a different way of thinking from your normal clinical routine. It has
really benefitted programmes as well, particularly in the monitoring and evaluation of
programmes. … It’s quite impressive what these networks have done.”
— Study Investigator, Projet Ubuzima, Rwanda

Endnotes
1 UNAIDS/WHO, “AIDS Epidemic Update”, November 2009
2 UNAIDS, “Report on the global AIDS epidemic”, August 2008
3 WHO, “The Global Burden of Disease, Update 2004”, Geneva, 2008
4 Swaziland Ministry of Health & Welfare, “11th HIV sentinel surveillance
report”, February 2009
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